NLRP3 and hepatocellular carcinoma: Because all results support that a deletion of NLRP3 in HCC inhibits their development and metastasis through the control of their mechanism and an induction of NK cytotoxicity, we thus decide that to target NLRP3 in human HCC is good to NK cell immunotherapy.